RT Journal Article
SR Electronic
T1 Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 379
OP 383
DO 10.1111/j.1525-1438.2007.01023.x
VO 18
IS 2
A1 A. Jaishuen
A1 J. P. Berrios-Rivera
A1 N. Sirisabya
A1 H. G. Zheng
A1 Y. Li
A1 J. J. Kavanagh
YR 2008
UL http://ijgc.bmj.com/content/18/2/379.abstract
AB Bevacizumab (BVC) is currently used in recurrent ovarian cancer and as part of the initial treatment for ovarian cancer. The most serious toxicities associated with BVC include gastrointestinal perforations, delayed wound healing, and hemorrhage. Arthritis had never been addressed in patients who received BVC treatment. This is the first case report of arthritis emergence linked to BVC administration. A 59-year-old female with recurrent ovarian cancer received multiple hormonal and cytotoxic regimens for 5 years and then developed erosive osteoarthritis of the hands secondary to BVC and paclitaxel. This effect was confirmed by a significant improvement in her symptoms and signs, after treatment was discontinued.